Market closedNon-fractional

Lineage Cell Therapeutics/LCTX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Lineage Cell Therapeutics

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

Ticker

LCTX

Sector

Healthcare

Trading on

AMEX

Industry

Biotechnology

Headquarters

Carlsbad, United States

Employees

72

LCTX Metrics

BasicAdvanced
$169M
Market cap
-
P/E ratio
-$0.13
EPS
1.31
Beta
-
Dividend rate
$169M
1.31
2.707
2.587
3.033
4.584
-11.97%
-33.76%
19.623
2.33
11.09
-6.646
-32.48%
-2.98%
67.50%
14.44%

What the Analysts think about LCTX

Analyst Ratings

Majority rating from 6 analysts.
Buy

LCTX Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-464.28% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$1.4M
-30.00%
Net income
-$6.5M
38.30%
Profit margin
-464.28%
97.57%

LCTX Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 4.35%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.03
-$0.04
-$0.03
-$0.04
-
Expected
-$0.04
-$0.04
-$0.04
-$0.04
-$0.05
Surprise
-32.26%
-6.67%
-30.00%
4.35%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Lineage Cell Therapeutics stock?

Lineage Cell Therapeutics (LCTX) has a market cap of $169M as of July 06, 2024.

What is the P/E ratio for Lineage Cell Therapeutics stock?

The price to earnings (P/E) ratio for Lineage Cell Therapeutics (LCTX) stock is 0 as of July 06, 2024.

Does Lineage Cell Therapeutics stock pay dividends?

No, Lineage Cell Therapeutics (LCTX) stock does not pay dividends to its shareholders as of July 06, 2024.

When is the next Lineage Cell Therapeutics dividend payment date?

Lineage Cell Therapeutics (LCTX) stock does not pay dividends to its shareholders.

What is the beta indicator for Lineage Cell Therapeutics?

Lineage Cell Therapeutics (LCTX) has a beta rating of 1.31. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell Lineage Cell Therapeutics stock

Buy or sell Lineage Cell Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing